Special donor immune cells after stem cell transplant for high-risk blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-risk blood cancer (like leukemia, lymphoma, or myelodysplastic syndrome) that hasn't responded to other treatments or has come back.
- Your stem cell donor is a blood relative and can be a full match, partial match, or half match.
- You are able to perform daily activities with little help (ECOG score 0-2).
- Your liver, kidney, and lung function are within safe limits before the transplant.
- You agree to use birth control if there is any chance of pregnancy.
- You understand the study and are willing to follow all procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called iNKT cells) given after a donor stem cell transplant for blood cancers. The goal is to see if these cells are safe and can help prevent the cancer from coming back.
This trial uses donor immune cells (lymphocytes) after a stem cell transplant to help fight any remaining cancer in people with high-risk blood cancers. It aims to lower the chance of the cancer coming back.
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
Hear when a new Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.